Bio3, Creabilis sign research agreements with Cephalon for K252a for psoriasis, restenosis

By Angela McDaniels

Seattle, Dec. 1 - Bio3 Research Srl and Creabilis Therapeutics SpA said they have signed an agreement with Cephalon Inc. to evaluate the research compound K252a as a treatment for psoriasis and for potential use in the prevention and treatment of restenosis.

Cephalon has proprietary rights in certain production processes for the compound.

Creabilis owns patent applications covering K252a-based products for the treatment of psoriasis. Bio3 and Creabilis co-own a patent application covering the use of K252a to prevent and treat restenosis and other cardiovascular disorders.

Under the new agreement, Cephalon has an exclusive option to develop and commercialize K252a-based products that may result from research performed by Creabilis and Bio3.

Bio3 Research retains the right to collaborate with third parties in combining K252a with drug-eluting stents to prevent and treat restenosis.

Other terms of the agreements were not disclosed.

"This agreement with Cephalon is a great opportunity for Creabilis Therapeutics because it enables us to accelerate the development process of this promising compound," said Creabilis chief executive officer Silvano Fumero in a company news release.

Creabilis said it expects to file Investigational New Drug Applications by the end of 2006.

Creabilis is a drug-discovery and development company focused on DNA-binding proteins and located in Collertto Giascosa, Italy.

Bio3 has headquarters in Milan and works with research institutions, individual scientists and early stage companies to identify intellectual properties in the life sciences.

Cephalon is a Frazer, Pa.-based biopharmaceutical company that specializes in developing drugs to treat and manage neurological diseases, sleep disorders, cancer and pain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.